靶向口服抗凝药给华法林带来的新思路  

New challenge of target-specific anticoagulants replacing warfarin

作　　者：况赟 赖青[1] 杨双[2] 龚丽英[2] 项玉霞[2] 李静乐[2] 阳国平[2] 

机构地区：[1]中南大学药学院,长沙410013 [2]中南大学湘雅三医院临床药理中心,长沙410013

出　　处：《中国临床药理学杂志》2016年第5期473-475,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(81373476);科技部国际科技合作与交流专项基金资助项目(2014DFA30900)

摘　　要：华法林是唯一的口服抗凝药物,广泛应用于血栓栓塞事件的预防,其抗栓疗效已很明确,但也存在一些缺陷,如华法林治疗窗窄,个体化差异大。新型靶向口服抗凝药物的出现为抗凝药物提供了新的选择。因此,本文针对靶向口服抗凝药物研究进展进行概述,来探讨靶向口服抗凝药给华法林带来的新思路。Warfarin was the only oral anticoagulant drug,widely used in the prevention of thromboembolism events. The antithrombotic effect of warfarin has been very clear,but there are also some defects,such as that the treatment window is narrow and individual difference is very big.In recent years,the emergence of new targeted oral anticoagulant agents has provided a new choice for the anticoagulant drugs. The development of targeted oral anticoagulant drugs is reviewed,and the new challenge to warfarin is discussed.

关 键 词：靶向口服抗凝药 华法林 心房颤动 深静脉血栓 

分 类 号：R973.2[医药卫生—药品]